Ferns R B, Tuke P W, Sweenie C H
Department of Virology, University College London Medical School, United Kingdom.
J Med Virol. 1996 Nov;50(3):221-9. doi: 10.1002/(SICI)1096-9071(199611)50:3<221::AID-JMV3>3.0.CO;2-B.
Hepatitis C virus (HCV) has as yet no practical culture system so any antigen or antibody studies must be carried out using recombinant antigens. In this study, HCV core sequence was amplified by PCR, inserted into pRSET, and expressed in E. coli. The resultant core protein was purified using nickel affinity chromatography which bound the six histidine tag attached to the N-terminus of the protein. After elution in imidazole buffer, the core protein was used to immunise Balb/c mice and monoclonal antibodies against HCV core were raised. Six monoclonals were examined in a variety of assays. All of them recognised the p27 kDa protein which they were raised against and 2D2 and 3D7 recognised the core component of an HCV Recombinant Immunoblot Assay (RIBA). None of the antibodies recognised the linear peptides in an Innolia HCV assay. 2D2 showed cytoplasmic granular staining in 1-5% of cells in frozen section of HCV infected livers. Cross-competition assays between themselves and human anti-HCV core positive sera divided the antibodies into two main groups (I and II), with a sub-division of group I into a and b. Group I antibodies were unable to be inhibited by human anti-HCV sera whereas group II antibodies were inhibited by these sera (up to 62%). Epitopes recognised by all the monoclonals were probably conformational with the group I epitope being located within the first 105 amino acids of the core sequence and the group II epitope between amino acids 105 and 160.
丙型肝炎病毒(HCV)目前尚无实用的培养系统,因此任何抗原或抗体研究都必须使用重组抗原来进行。在本研究中,通过聚合酶链反应(PCR)扩增HCV核心序列,将其插入pRSET载体,并在大肠杆菌中表达。使用镍亲和层析法纯化所得的核心蛋白,该方法可结合与该蛋白N端相连的六个组氨酸标签。在咪唑缓冲液中洗脱后,用核心蛋白免疫Balb/c小鼠,并制备了抗HCV核心的单克隆抗体。对六种单克隆抗体进行了多种检测。所有单克隆抗体都识别其针对的p27 kDa蛋白,2D2和3D7识别HCV重组免疫印迹分析(RIBA)的核心成分。在Innolia HCV检测中,没有一种抗体识别线性肽段。在HCV感染肝脏的冰冻切片中,2D2在1%-5%的细胞中显示出胞质颗粒染色。它们自身之间以及与人类抗HCV核心阳性血清的交叉竞争试验将这些抗体分为两个主要组(I和II),I组又细分为a和b亚组。I组抗体不能被人类抗HCV血清抑制,而II组抗体可被这些血清抑制(高达62%)。所有单克隆抗体识别的表位可能是构象性的,I组表位位于核心序列的前105个氨基酸内,II组表位位于第105至160个氨基酸之间。